{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T15:17:01Z","timestamp":1787584621834,"version":"build-2736575974"},"reference-count":23,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2020,12,31]],"date-time":"2020-12-31T00:00:00Z","timestamp":1609372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["671055"],"award-info":[{"award-number":["671055"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathogens"],"abstract":"<jats:p>A clinical trial performed in the Democratic Republic of Congo (DRC), among persons with epilepsy (PWE) infected with Onchocerca volvulus treated with anti-seizure medication suggested that ivermectin reduces the seizure frequency. We assessed the effect of ivermectin treatment on seizure frequency in PWE with and without anti-seizure medication in three onchocerciasis endemic areas (Maridi, South Sudan; Aketi, DRC; and Mahenge, Tanzania). Pre- and 3\u20135 months post-ivermectin microfilariae densities in skin snips and seizure frequency were assessed. After ivermectin, the median (IQR) percentage reduction in seizure frequency in the study sites ranged from 73.4% (26.0\u201390.0) to 100% (50.0\u2013100.0). A negative binomial mixed model showed that ivermectin significantly reduced the seizure frequency, with a larger decrease in PWE with a high baseline seizure frequency. Mediation analysis showed that ivermectin reduced the seizure frequencies indirectly through reduction in microfilariae densities but also that ivermectin may have a direct anti-seizure effect. However, given the short half-life of ivermectin and the fact that ivermectin does not penetrate the healthy brain, such a direct anti-seizure effect is unlikely. A randomized controlled trial assessing the ivermectin effect in people infected with O. volvulus who are also PWE on a stable anti-seizure regimen may be needed to clarify the causal relationship between ivermectin and seizure frequency.<\/jats:p>","DOI":"10.3390\/pathogens10010021","type":"journal-article","created":{"date-parts":[[2020,12,31]],"date-time":"2020-12-31T10:10:37Z","timestamp":1609409437000},"page":"21","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Effect of Ivermectin Treatment on the Frequency of Seizures in Persons with Epilepsy Infected with Onchocerca volvulus"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2660-880X","authenticated-orcid":false,"given":"Alfred","family":"Dusabimana","sequence":"first","affiliation":[{"name":"Global Health Institute, University of Antwerp, Doornstraat 331, 2610 Antwerp, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6405-015X","authenticated-orcid":false,"given":"Solomon","family":"Tsebeni Wafula","sequence":"additional","affiliation":[{"name":"Global Health Institute, University of Antwerp, Doornstraat 331, 2610 Antwerp, Belgium"},{"name":"Department of Disease Control and Environmental Health, Makerere University, Kampala P.O. Box 7072, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen Jada","family":"Raimon","sequence":"additional","affiliation":[{"name":"Amref Health Africa, Juba P.O. Box 30125, South Sudan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3544-1239","authenticated-orcid":false,"given":"Joseph Nelson Siewe","family":"Fodjo","sequence":"additional","affiliation":[{"name":"Global Health Institute, University of Antwerp, Doornstraat 331, 2610 Antwerp, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Bhwana","sequence":"additional","affiliation":[{"name":"National Institute of Medical Research, Tanga Centre, Tanga P.O. Box 5004, Tanzania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floribert","family":"Tepage","sequence":"additional","affiliation":[{"name":"Ministry of Health, Bas U\u00e9l\u00e9 Province, Buta B.P. 105, Democratic Republic of Congo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gasim","family":"Abd-Elfarag","sequence":"additional","affiliation":[{"name":"Amsterdam Institute for Global Health and Development, Paasheuvelweg 25, 1105 BP Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3356-4032","authenticated-orcid":false,"given":"An","family":"Hotterbeekx","sequence":"additional","affiliation":[{"name":"Global Health Institute, University of Antwerp, Doornstraat 331, 2610 Antwerp, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7353-9304","authenticated-orcid":false,"given":"Steven","family":"Abrams","sequence":"additional","affiliation":[{"name":"Global Health Institute, University of Antwerp, Doornstraat 331, 2610 Antwerp, Belgium"},{"name":"Data Science Institute, Interuniversity Institute for Biostatistics and Statistical Bioinformatics, Hasselt University, 3590 Diepenbeek, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1919-1340","authenticated-orcid":false,"given":"Robert","family":"Colebunders","sequence":"additional","affiliation":[{"name":"Global Health Institute, University of Antwerp, Doornstraat 331, 2610 Antwerp, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,12,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.pt.2017.11.009","article-title":"Onchocerciasis-associated epilepsy, an additional reason for strengthening onchocerciasis elimination programs","volume":"34","author":"Colebunders","year":"2018","journal-title":"Trends Parasitol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"861","DOI":"10.2165\/00003495-199652060-00007","article-title":"Treatment of onchocerciasis","volume":"52","author":"Lopes","year":"1996","journal-title":"Drugs"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1186\/1475-2883-2-S1-S5","article-title":"Possible pathogenic pathways in the adverse clinical events seen following ivermectin administration to onchocerciasis patients","volume":"2","author":"Mackenzie","year":"2003","journal-title":"Filaria J."},{"key":"ref_4","first-page":"193","article-title":"Reactions to ivermectin treatment in onchocerciasis patients","volume":"59","author":"Awadzi","year":"1990","journal-title":"Acta Leiden"},{"key":"ref_5","first-page":"375","article-title":"A community trial of ivermectin in the onchocerciasis focus of Asubende, Ghana. II. Adverse reactions","volume":"40","author":"Awadzi","year":"1989","journal-title":"Trop. Med. Parasitol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/inthealth\/ihv038","article-title":"Community-directed interventions are practical and effective in low-resource communities: Experience of ivermectin treatment for onchocerciasis control in Cameroon and Uganda, 2004\u20132010","volume":"8","author":"Katabarwa","year":"2016","journal-title":"Int. Health"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S1473-3099(08)70099-9","article-title":"Effect of single-dose ivermectin on Onchocerca volvulus: A systematic review and meta-analysis","volume":"8","author":"Basanez","year":"2008","journal-title":"Lancet Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/0140-6736(92)92329-E","article-title":"Improvement in seizures after ivermectin","volume":"340","author":"Kipp","year":"1992","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Siewe Fodjo, J.N., Mandro, M., Mukendi, D., Tepage, F., Menon, S., Nakato, S., Nyisi, F., Abhafule, G., Wonya\u2019rossi, D., and Anyolito, A. (2019). Onchocerciasis-associated epilepsy in the Democratic Republic of Congo: Clinical description and relationship with microfilarial density. PLoS Negl. Trop. Dis., 13.","DOI":"10.1101\/577247"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.2196\/resprot.7186","article-title":"Ivermectin treatment in patients with onchocerciasis-associated epilepsy: Protocol of a randomized clinical trial","volume":"6","author":"Colebunders","year":"2017","journal-title":"JMIR Res. Protoc."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Mandro, M., Siewe Fodjo, J.N., Dusabimana, A., Mukendi, D., Haesendonckx, S., Lokonda, R., Nakato, S., Nyisi, F., Abhafule, G., and Wonya\u2019rossi, D. (2020). Single versus multiple dose ivermectin regimen in onchocerciasis-infected persons with epilepsy treated with phenobarbital: A randomized clinical trial in the democratic Republic of Congo. Pathogens, 9.","DOI":"10.20944\/preprints202001.0259.v1"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Dusabimana, A., Bhwana, D., Raimon, S., Mmbando, B.P., Hotterbeekx, A., Tepage, F., Mandro, M., Siewe Fodjo, J.N., Abrams, S., and Colebunders, R. (2020). Ivermectin treatment response in onchocerca volvulus infected persons with epilepsy: A three-country short cohort study. Pathogens, 9.","DOI":"10.3390\/pathogens9080617"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Levick, B., Laudisoit, A., Tepage, F., Ensoy-Musoro, C., Mandro, M., Bonareri Osoro, C., Suykerbuyk, P., Kashama, J.M., Komba, M., and Tagoto, A. (2017). High prevalence of epilepsy in onchocerciasis endemic regions in the Democratic Republic of the Congo. PLoS Negl. Trop. Dis., 11.","DOI":"10.1371\/journal.pntd.0005732"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ijid.2018.10.021","article-title":"High prevalence of epilepsy in an onchocerciasis endemic health zone in the Democratic Republic of the Congo, despite 14 years of community-directed treatment with ivermectin: A mixed-method assessment","volume":"79","author":"Mukendi","year":"2019","journal-title":"Int. J. Infect. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.seizure.2018.11.004","article-title":"High prevalence of onchocerciasis-associated epilepsy in villages in Maridi County, Republic of South Sudan: A community-based survey","volume":"63","author":"Colebunders","year":"2018","journal-title":"Seizure"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s40249-018-0450-3","article-title":"High prevalence of epilepsy in two rural onchocerciasis endemic villages in the Mahenge area, Tanzania, after 20 years of community directed treatment with ivermectin","volume":"7","author":"Mmbando","year":"2018","journal-title":"Infect. Dis. Poverty"},{"key":"ref_17","unstructured":"WHO (2018, March 06). African Programme for Onchocerciasis Control (APOC): Ivermectin. Available online: https:\/\/www.who.int\/apoc\/cdti\/ivermectin\/en\/."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"660","DOI":"10.2471\/BLT.07.043497","article-title":"Development of a WHO growth reference for school-aged children and adolescents","volume":"85","author":"Onyango","year":"2007","journal-title":"Bull. World Health Organ."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1093\/biostatistics\/kxv029","article-title":"Causal mediation analysis for longitudinal data with exogenous exposure","volume":"17","author":"Bind","year":"2016","journal-title":"Biostatistics"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Abd-Elfarag, G., Carter, J.Y., Raimon, S., Sebit, W., Suliman, A., Siewe Fodjo, J.N., Claver Olore, P., Biel, K.P., Ojok, M., and Logora, M.Y. (2020). Persons with onchocerciasis-associated epilepsy with nodding seizures have a more severe form of epilepsy, with more cognitive impairment and higher levels of Onchocerca volvulus infection. Epileptic Disord., in press.","DOI":"10.1684\/epd.2020.1164"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"382","DOI":"10.4269\/ajtmh.17-0042","article-title":"Serious neurological adverse events after ivermectin\u2013Do they occur beyond the indication of onchocerciasis?","volume":"98","author":"Chandler","year":"2018","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/clpt.1993.46","article-title":"Protein binding and ivermectin estimations in patients with onchocerciasis","volume":"53","author":"Okonkwo","year":"1993","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_23","first-page":"303","article-title":"Ivermectin as an adjunct in the treatment of refractory epilepsy","volume":"65","author":"Costa","year":"2017","journal-title":"Rev. Neurol."}],"container-title":["Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-0817\/10\/1\/21\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:48:17Z","timestamp":1760179697000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-0817\/10\/1\/21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,31]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,1]]}},"alternative-id":["pathogens10010021"],"URL":"https:\/\/doi.org\/10.3390\/pathogens10010021","relation":{},"ISSN":["2076-0817"],"issn-type":[{"value":"2076-0817","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,31]]}}}